WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H408180
Description: TD52 is an erlotinib derivative. TD52 is a putative inhibitor of CIP2A that exhibits potent antitumor efficacy on HCC and TNBC cells. TD52 induces apoptosis through downregulation of CIP2A (Cancerous inhibitor of protein phosphatase 2A) in HCC, NSCLC and TNBC cells.
Hodoodo Cat#: H408180
Chemical Formula: C24H16N4
Exact Mass: 360.1375
Molecular Weight: 360.42
Elemental Analysis: C, 79.98; H, 4.47; N, 15.55
Synonym: TD52; TD-52; TD 52; erlotinib derivative; erlotinib analogue;
IUPAC/Chemical Name: N2,N3-bis(3-ethynylphenyl)quinoxaline-2,3-diamine
InChi Key: SCUPZFSEJFWQIS-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H16N4/c1-3-17-9-7-11-19(15-17)25-23-24(26-20-12-8-10-18(4-2)16-20)28-22-14-6-5-13-21(22)27-23/h1-2,5-16H,(H,25,27)(H,26,28)
SMILES Code: C#CC1=CC=CC(NC2=NC3=CC=CC=C3N=C2NC4=CC=CC(C#C)=C4)=C1
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 360.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Liu CY, Huang TT, Huang CT, Hu MH, Wang DS, Wang WL, Tsai WC, Lee CH, Lau KY, Yang HP, Chen MH, Shiau CW, Tseng LM, Chen KF. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple- negative breast cancer cells. Eur J Cancer. 2017 Feb;72:112-123. doi: 10.1016/j.ejca.2016.11.012. Epub 2016 Dec 24. PMID: 28027514.
2: Yu HC, Hung MH, Chen YL, Chu PY, Wang CY, Chao TT, Liu CY, Shiau CW, Chen KF. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death Dis. 2014 Jul 31;5(7):e1359. doi: 10.1038/cddis.2014.325. PMID: 25077545; PMCID: PMC4123111.
3: Crugliano T, Quaresima B, Gaspari M, Faniello MC, Romeo F, Baudi F, Cuda G, Costanzo F, Venuta S. Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation. Int J Biochem Cell Biol. 2007;39(1):220-6. doi: 10.1016/j.biocel.2006.08.005. Epub 2006 Aug 30. Erratum in: Int J Biochem Cell Biol. 2017 Jul;88:236-237. PMID: 17005433.
Protein phosphatase 2A (PP2A) is a tumor suppressor, which is functionally defective in various cancers. Previously, we found that PP2A activity determined the anticancer effect of bortezomib and erlotinib in hepatocellular carcinoma (HCC) cell